FDA Bans Compounded Obesity Drugs: High Costs and Shortages Continue
Due to resolved shortages of Eli Lilly’s weight-loss and diabetes medications, Zepbound and Mounjaro, the FDA has ordered a phase-out of copycat versions sold by specialty and online pharmacies. This decision, effective within 60-90 days, benefits Lilly and potentially impacts patient access and costs. The FDA cited improved supply and safety concerns regarding the compounded drugs as reasons for the action. This reversal follows an earlier decision that was met with public opposition and legal challenge.
John Q. Hosedrinker